How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

458 results for

McMurray Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Hypertrophic Cardiomyopathy

of ventricular morphology and function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2745 5.5.2 Myocardial ?brosis . . . . . . . . . . . . . . . . . . . . . .2746 5.5.3 Late Gadolinium Enhancement and Prognosis . . . . .2746 5.5.4 Differential diagnosis . . . . . . . . . . . . . . . . . . . . .2746 5.6 Nuclear imaging and computerized tomography . . . . . .2747 5.7 Endomyocardial biopsy . . . . . . . . . . . . . . . . . . . . . .2747 5.8 Laboratory tests (...) . . . . . . . . . . . . . . . . . . . . . . . . . . .2747 6. Genetic testing and family screening . . . . . . . . . . . . . . . . . .2747 6.1 Counselling in probands . . . . . . . . . . . . . . . . . . . . . .2748 6.2 Methods for molecular genetic screening in probands . . .2748 6.3 Indications for genetic testing in probands . . . . . . . . . .2748 6.4 Genetic and clinical screening of relatives . . . . . . . . . . .2749 6.4.1 Families with de?nite disease causing genetic mutations 2749 6.4.2 Families without de?nite disease causing genetic

2014 European Society of Cardiology

202. ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management Full Text available with Trip Pro

. .2390 3.3 Functional capacity. . . . . . . . . . . . . . . . . . . . . . . . .2390 3.4 Risk indices . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2391 3.5 Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2392 3.6 Non-invasive testing. . . . . . . . . . . . . . . . . . . . . . . .2392 3.6.1 Non-invasive testing of cardiac disease . . . . . . . . .2393 3.6.2 Non-invasive testing of ischaemic heart disease. . . .2393 3.7 Invasive coronary angiography (...) failure, hypertension, age =75 (doubled), dia- betes, stroke (doubled)-vascular disease, age 65–74 and sex category (female) CI con?dence interval CI-AKI contrast-induced acute kidney injury CKD chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration C max maximum concentration CMR cardiovascular magnetic resonance COPD chronic obstructive pulmonary disease CPG Committee for Practice Guidelines CPX/CPET cardiopulmonary exercise test CRP C-reactive protein CRT cardiac

2014 European Society of Cardiology

203. Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Cardiol. 2013 Oct 26. PubMed: PM24211508 6. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549-58. PubMed: PM24016506 7. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, et al. Left ventricular systolic dysfunction (...) and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749-58. PubMed: PM23036896 14. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. PubMed: PM21309657 15. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

204. The characteristic findings of an inverted-type discoid lateral meniscus tear: a hidden tear pattern. Full Text available with Trip Pro

(inverted group). We age-matched these patients with 12 controls who were extracted from many normal DLM tear cases in the same period (non-inverted group). The assessment items were traumatic history with the onset of pain, the mean duration between the appearance of symptoms and surgery, preoperative knee range of motion (ROM), positive findings on the McMurray test, knee locking or catching, and characteristic MRI findings. These items were compared between the two groups using χ2 and Student's t (...) -tests.All patients in the inverted group had clear trauma with the onset of pain during sports or daily life activities, and 7 of the 12 patients with a non-inverted type of DLM tear had clear trauma. There was a significantly higher rate of traumatic history in the inverted group than in the non-inverted group (P = 0.03). The mean duration between the appearance of symptoms and surgery, preoperative knee ROM, positive findings on the McMurray test, and knee locking or catching were not significantly

2019 BMC Musculoskeletal Disorders

205. Magnetic resonance imaging can increase the diagnostic accuracy in symptomatic meniscal repair patients. (Abstract)

included. All had undergone a primary meniscal repair followed by an MRI and re-arthroscopy due to clinical symptoms of a meniscal lesion. A validated semi-quantitative scoring system was employed for identifying MRI-diagnosed healing failure. The clinical assessment was divided into joint swelling, joint-line tenderness, locking and a positive McMurray's test. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of MRI and positive clinical findings were

2019 Knee Surgery, Sports Traumatology, Arthroscopy

206. Antithrombotics: indications and management

with antithrombotics and their management should be evidence based. Developments since the publication of SIGN 36: Antithrombotic Therapy in 1999 include the introduction to clinical practice of novel antithrombotics (for example orally active inhibitors of thrombin and activated factor X), changes to models of care (including patient self testing and self dosing for warfarin) and exploration of new indications for antithrombotics (for example recurrent miscarriage). This guideline complements, and should be used (...) clinical assessment has demonstrated an indication for heparin treatment, the patient’s medical and drug history should be assessed and baseline blood tests including platelet count, coagulation screen (in order to check baseline APTT ratio is normal), urea, electrolytes and liver function tests should be obtained. These may reveal contraindications or risk factors for bleeding, such as anaemia, thrombocytopenia, renal failure, or coagulopathy (eg due to severe liver disease). 9 A baseline platelet

2012 SIGN

207. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: Blood pressure measurement, diagnosis, assessment of risk, and therapy

experts using prespecified levels of evidence. Recommendations Diagnosis and assessment A new recommendation this year relates to the diagnosis of white coat hypertension, which could be confirmed either by reliable repeated home blood pressure (BP) monitoring or 24-hour ambulatory BP monitoring (ABPM). Recommendations for BP measurement, criteria for hypertension diagnosis and follow-up, assessment of global cardiovascular risk, diagnostic testing, diagnosis of renovascular and endocrine causes (...) on the CHEP recommendations is to provide timely evidence-based recommendations to primary care providers to improve hypertension prevention, detection, and control in Canadians. Key clinical questions addressed include: (1) How is hypertension diagnosed? (2) How do we diagnose white coat hypertension? (3)What frequency of follow-up and laboratory testing is necessary for hypertensive patients? (4) How is risk assessed for future cardiovascular events in these patients? (5) When should we start

2012 CPG Infobase

208. Knee Pain and Mobility Impairments: Meniscal and Articular Cartilage Lesions

, maximum passive knee ?exion, McMurray’s maneuver, and palpation for joint-line tenderness. D Clinicians may administer the appropriate physical impair- ment assessments of body structure and function, at least at baseline and at discharge or 1 other follow-up point, for all patients with articular cartilage lesions to support standardization for quality improvement in clinical care and research, including the modi?ed stroke test for effusion assessment, assessment of knee active range of motion (...) or ?eld tests, such as single-legged hop tests (eg, single hop for distance, cross- over hop for distance, triple hop for distance, and 6-m timed hop), that can identify a patient’s baseline status relative to pain, function, and dis- ability; detect side-to-side asymmetries; assess global knee function; de- termine a patient’s readiness to return to activities; and monitor changes in the patient’s status throughout the course of treatment. EXAMINATION – PHYSICAL IMPAIRMENT MEASURES 2018

2018 The Orthopaedic Section of the American Physical Therapy Association (APTA), Inc.

209. Chest X-rays for Diagnosing Pulmonary Infection as a Precipitant of Acute Heart Failure

precipitant of an HF exacerbation. (2) Technology Radiography is the application of x-rays to produce an image based on the internal physical properties of an object. By exploiting known physical properties of the human body, an image of internal structures and organs can be created. X-ray imaging tools are widely available and non-invasive. Pneumonia is typically diagnosed using a combination of clinical exams, chest x-ray, and laboratory tests. (9) Other diagnostic imaging tools for pneumonia include (...) , management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol. 2007 Jan;23(1):21-45. (5) Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e1-194. (6) McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis

2013 Health Quality Ontario

210. RE?LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation

were excluded. ? 77% of patients were managed at primary care centres. 15% were managed at anticoagulation clinics. ? Mean (SD): TTR 64% (20%), monthly frequency of INR testing 1.6 (1.3), time below therapeutic range 22% (19%) & above therapeutic range 13% (13%). - North American data (n=2167, 36%): mean (SD) TTR 67% (17%), algorithm consistency 64% (17%), time below therapeutic range 19% (15%) & above therapeutic range 14% (11%). ? Warfarin dose adjustments based on the above recommendations were (...) =diabetes ECG=electrocardiogram GI=gastrointestinal HF=heart failure Hgb=hemoglobin H 2 RA=histamine-2 receptor antagonist HTN=hypertension INR=international normalized ratio LFT=liver function test LVEF=left ventricular ejection fraction MI=myocardial infarction NNT=number needed to treat NNH=number needed to harm NS=not statistically significant NYHA=New York Heart Association PE=pulmonary embolism PPI=proton pump inhibitor TIA=transient ischemic attack VKA=vitamin K antagonist yr=year

2013 RxFiles

211. Diabetes, Pre-Diabetes and Cardiovascular Diseases

dinucleotide phosphate hydrogen NDR National Diabetes Register NHANES NationalHealth and NutritionExamination Survey ESC Guidelines 3038 Downloaded from https://academic.oup.com/eurheartj/article-abstract/34/39/3035/503593 by guest on 02 April 2019NICE National Institute for Health and Clinical Excel- lence (UK) NNT number needed to treat NO nitric oxide NOAC new oral anticoagulants NYHA New York Heart Association OAT Occluded Artery Trial OGTT oral glucose tolerance test OMT optimal medical treatment (...) Health Organization (WHO) and the American Diabetes Associ- ation (ADA). 2– 6 Glycated haemoglobin A 1c (HbA 1c ) has been recommended as a diagnostic test for DM, 7,8 but there remain con- cerns regarding its sensitivity in predicting DM and HbA 1c values ,6.5% do not exclude DM that may be detected by blood glucose measurement, 7 –10 as further discussed in Section 3.3. Four main aetiological categories of DM have been identi?ed: type 1 diabetes (T1DM), T2DM, ‘other speci?c types’ of DM

2013 European Society of Cardiology

212. Management of Arterial Hypertension

) Abnormal glucose tolerance test Obesity [BMI =30 kg/m 2 (height 2 )] Abdominal obesity (waist circumference: men =102 cm; women =88 cm) (in Caucasians) Family history of premature CVD (men aged 3.5 mV; RaVL >1.1 mV; Cornell voltage duration product >244 mV*ms), or Echocardiographic LVH [LVM index: men >115 g/m 2 ; women >95 g/m 2 (BSA)] a Carotid wall thickening (IMT >0.9 mm) or plaque Carotid–femoral PWV >10 m/s Ankle-brachial index 7% (53 mmol/mol), and/or Post-load plasma glucose >11.0 mmol/L (198

2013 European Society of Cardiology

213. Management of Stable Coronary Artery Disease

investigations . . . . . . . . . . . . . . .2958 6.2.1 Basic testing . . . . . . . . . . . . . . . . . . . . . . . . . . .2958 6.2.1.1 Biochemical tests (see web addenda) . . . . . . . . .2958 6.2.1.2 Resting electrocardiogram . . . . . . . . . . . . . . . .2960 6.2.1.3 Echocardiography at rest (see web addenda) . . . .2960 6.2.1.4 Cardiac magnetic resonance at rest . . . . . . . . . . .2960 6.2.1.5 Ambulatory electrocardiogram monitoring . . . . . .2961 6.2.1.6 Chest X-ray (...) . . . . . . . . . . . . . . . . . . . . . . . . .2961 6.2.2 Three major steps used for decision-making . . . . . .2961 6.2.3 Principles of diagnostic testing . . . . . . . . . . . . . . .2961 6.2.4 Stress testing for diagnosing ischaemia . . . . . . . . . .2963 6.2.4.1 Electrocardiogram exercise testing . . . . . . . . . . .2963 6.2.4.2 Stress imaging (see web addenda) . . . . . . . . . . . .2965 6.2.4.2.1 Stress echocardiography . . . . . . . . . . . . . .2965 6.2.4.2.2 Myocardial perfusion scintigraphy (single photon emission computed

2013 European Society of Cardiology

214. Findings series 41 - Public health implications of the pSoBid study

, participants completed lifestyle and psychological questionnaires and underwent measurement of blood pressure, heart rate, hip, waist and mid-thigh circumference and assessment of lung function. At visit 2, participants were asked to fast before attending, so bloods could be taken for biochemical analyses. Height and weight were measured. After being provided with breakfast, subjects completed a number of cognitive tests. Finally, carotid artery ultrasound, a non-invasive measure of atherosclerosis (...) 21 , the Rosenberg Self-esteem Scale 22 and the Eysenck Personality Questionnaire 23 . A series of cognitive tests were completed and included the Trail Making Test 24 , the Stroop Test 25 , the Choice Reaction Time Test 26 , the Auditory Verbal Learning Test 27 and the National Adult Reading Test 28 . b Magnetic resonance imaging (MRI) is a medical imaging technique most commonly used to visualise detailed internal body structures that do not show up well on x-rays. Public health implications

2014 Glasgow Centre for Population Health

215. Electrocardiograms for Diagnosing Ischemia as a Precipitant to Acute Heart Failure

) McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33(14):1787-847. (7) National Institute for Health and Clinical Excellence. Chest pain of recent onset (...) : description of population. Eur Heart J. 2006 Nov;27(22):2725-36. (10) Davenport C, Cheng EY, Kwok YT, Lai AH, Wakabayashi T, Hyde C et al. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. Br J Gen Pract. 2006 Jan;56(522):48-56. (11) Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, Jr. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients

2012 Health Quality Ontario

216. Inotropic and Vasoactive Agents for In-Hospital Heart Failure Management

: Literature Search Strategies 14 Appendix 2: GRADE Tables 16 References 17 . Inotropic and Vasoactive Agents for In-Hospital Heart Failure Management: A Rapid Review. December 2012; pp. 1–19. 5 List of Abbreviations AMSTAR Assessment of Multiple Systematic Reviews CI Confidence interval(s) HF Heart failure M-H Mantel-Haenszel test NYHA New York Heart Association RCT Randomized controlled trial RR Relative risk . Inotropic and Vasoactive Agents for In-Hospital Heart Failure Management: A Rapid Review (...) Management: A Rapid Review. December 2012; pp. 1–19. 17 References (1) Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002 Feb 6;287(5):628-40. (2) Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007 Jun;9(6-7):684-94. (3) Gheorghiade M, Abraham WT

2012 Health Quality Ontario

217. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

15mg* po daily versus dose-adjusted warfarin (INR 2-3 in patients <70 years of age & INR 1.6-2.6 in patients =70 years old). *rivaroxaban 10mg po daily in patients with CrCl 30-49 mL/min ? 22% of the patient population ? Safety: rivaroxaban was non-inferior to warfarin for the composite of major & non-major bleeding; individual composite endpoints not statistically significant when separated. Differences in location of bleeds were not tested for statistical significance. ? Efficacy: not powered (...) ://www.nejm.org/doi/full/10.1056/NEJMoa1009638 (ROCKET-AF) 2 Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med August 28, 2011 http://www.nejm.org/doi/pdf/10.1056/NEJMoa1107039 (ARISTOTLE) 3 Jin M. RxFiles Trial Summary – ARISTOTLE: Apixaban versus warfarin in patients with atrial fibrillation. Saskatoon, SK: RxFiles; 2011. Available from: www.rxfiles.ca. Accessed April 30 th , 2012. 4 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran

2012 RxFiles

218. Acute Myocardial Infarction in patients presenting with ST-segment elevation

on sound evidence, derived from well-conducted clinical trials. Because of the great number of trials on new treatments performed in recent years, and in view of new diagnostic tests, the ESC decided that it was opportune to upgrade the previous guidelines and appointed a Task Force. It must be recognized that, even when excellent clinical trials have been undertaken, their results are open to interpretation and that treatment options may be limited by resources. Indeed, cost-effectiveness is becoming (...) .) thrombolysis. A positive point-of-care troponin test 1–2 h after symptom onset in patients with BBB of uncertain origin may help decide whether to perform emergency angiog- raphy with a view to primary PCI. Patients with myocardial in- farction and RBBB also have a poor prognosis, 25 although RBBB usually will not hamper interpretation of ST-segment ele- vation. Prompt management should be considered when per- sistent ischaemic symptoms occur in the presence of RBBB, regardless of whether or not the latter

2012 European Society of Cardiology

219. CVD Prevention in clinical practice

McMurray (UK), Andrzej Paja ?k (Poland), Alexander Parkhomenko (Ukraine), Loukianos Rallidis (Greece), Fausto Rigo (Italy), Evangelista Rocha (Portugal), Luis Miguel Ruilope (Spain), Enno van der Velde (The Netherlands), Diego Vanuzzo (Italy), Margus Viigimaa (Estonia), Massimo Volpe (Italy), Olov Wiklund (Sweden), Christian Wolpert (Germany). The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org/guidelines Societies: 1 European Society of Cardiology (ESC

2012 European Society of Cardiology

220. Acute and Chronic Heart Failure

Acute and Chronic Heart Failure ESC GUIDELINES ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Authors/Task Force Members: John J.V. McMurray (Chairperson) (UK) * , Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Angelo Auricchio (Switzerland (...) ), Antonio Coca (Spain), Peter Cowburn (UK), Henry Dargie (UK), Perry Elliott (UK), Frank Arnold Flachskampf (Sweden), Guido Francesco Guida (Italy), Suzanna Hardman (UK), Bernard Iung * Corresponding author. Chairperson: Professor John J.V. McMurray, University of Glasgow G12 8QQ, UK. Tel:+44 141 330 3479, Fax:+44 141 330 6955, Email: john.mcmurray@ glasgow.ac.uk Other ESC entities having participated in the development of this document: Associations: European Association for Cardiovascular Prevention

2012 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>